Edit Stock Quote and Understand Editas Medicine Valuation

Editas Medicine is a biotech company that has been making waves in the stock market with its innovative gene editing technology. Editas Medicine's stock price has fluctuated significantly over the past year, with a high of $142.50 and a low of $32.50.

One of the key factors affecting Editas Medicine's stock price is its valuation. The company's market capitalization is around $3.5 billion, which is a significant increase from its initial public offering (IPO) price of $18 per share.

Investors are closely watching Editas Medicine's progress in developing its gene editing technology, which has the potential to revolutionize the treatment of genetic diseases. The company's stock price is likely to continue to be volatile as investors weigh the potential benefits and risks of its technology.

Editas Medicine, Inc. has recently received downgrades from various analysts. JPMorgan downgraded Editas Medicine to Underweight from Neutral on December 16.

Several analysts have downgraded Editas Medicine in the past week, including JonesTrading, Chardan, Stifel, and Truist Securities. They all downgraded the company's stock on December 13.

Here are the details of the downgrades:

The market capitalization of Editas Medicine, Inc has fluctuated between $125M and $13.72B over the years, with the most recent value being $23.69B.

In 2024, the P/E ratio for Editas Medicine, Inc was -0.72x, indicating a significant undervaluation of the company.

The enterprise value of Editas Medicine, Inc has also seen significant fluctuations, ranging from -$79.28M to -$11.85B, with the most recent value being -$11.85B.

The free-float of Editas Medicine, Inc is a high 99.68%, indicating a relatively low level of ownership concentration.

The EV/Sales ratio for Editas Medicine, Inc in 2024 was -1.93x, suggesting that the company's valuation is heavily influenced by its financial performance.

Here are the valuation metrics for Editas Medicine, Inc over the years:

Editas Medicine has received a string of downgrades from various analysts in recent days.

JPMorgan downgraded Editas Medicine to Underweight from Neutral on December 16.

Several analysts have downgraded Editas Medicine to Hold from Buy, including JonesTrading, Chardan, Stifel, and Truist Securities, all on December 13.

Here's a breakdown of the downgrades:

Chardan also withdrew its $12 price target for Editas Medicine.

Recently, analysts have been weighing in on Editas Medicine, Inc. JPMorgan downgraded the company to Underweight From Neutral on December 16.

Several analysts have downgraded Editas Medicine in the past week. On December 13, JonesTrading downgraded the company to Hold From Buy, Chardan downgraded it to Neutral From Buy, and Stifel downgraded it to Hold From Buy. Truist Securities also downgraded it to Hold From Buy on the same day.

Here are the specific downgrades that have occurred:

It's worth noting that Chardan also withdrew its $12 price target for Editas Medicine as part of its downgrade.